#Shingles

A large international study finds that adults over 50 who receive the shingles vaccine experience up to a 23% reduction in major cardiovascular events, including stroke, heart failure, and heart disease, with benefits lasting up to eight years. The match between shingles prevention and cardiovascular protection could reshape how Thailand and other aging populations approach preventive health.

Thailand is aging rapidly, and cardiovascular disease remains the leading cause of death. Health authorities highlight the potential of a single intervention to address two major health challenges: infectious disease and chronic illness. The World Health Organization notes that stroke and heart disease cause hundreds of thousands of Thai deaths each year, with risk rising after age 50. Traditional prevention focuses on lifestyle and medications, but vaccination is emerging as a powerful, often overlooked tool.

A new international study has found that adults over 50 who receive the shingles vaccine can dramatically reduce their risk of major cardiovascular events—including stroke, heart failure, and heart disease—by as much as 23% for up to eight years following vaccination. The findings, published in the European Heart Journal in early May and quickly covered by global outlets such as the European Society of Cardiology and Science Daily, mark a significant turning point for public health, suggesting that the benefits of the vaccine extend far beyond protection against the painful rash caused by herpes zoster.

A new study suggests that a vaccine commonly used to prevent shingles may also lower dementia risk in older adults. Published in Nature, the research found that people vaccinated against shingles had about a 20% lower chance of developing dementia over seven years. The findings add another reason for adults aged 50 and above to consider shingles vaccination, alongside preventing a painful rash and nerve complications.

For Thai readers, the implications are meaningful. Thailand’s population is aging, with more seniors at risk of dementia. If confirmed, the potential brain-health benefits of the shingles vaccine could support public health goals in the country. The Welsh-based study tracked roughly 280,000 medical records, comparing individuals who received the first-generation shingles vaccine with those who did not because of age-based eligibility.